Wolfgang Miesbach/LinkedIn
Jul 21, 2026, 19:41
Wolfgang Miesbach: SR604 Restores Thrombin Generation Where It Is Needed
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“New haemophilia treatment restoring thrombin generation where it is needed – with signals of lower inflammation.
Late-breaking at ISTH 2026 in Paris: the Phase IIb read-out for SR604, a subcutaneous anti-APC antibody dosed as infrequently as every 8 weeks.
Having posted on the biology yesterday, here are the study results:
- Design – open-label, multicentre; 0.4 mg/kg SC randomised to Q4W, Q6W, or Q8W; 24-week observation with a 24-week extension.
- Patients – 36 treated (28 haemophilia A, 8 B), with and without inhibitors.
- Efficacy – ABR fell approximately 91% in the Q4W cohort (from 37.3 to 3.3; 1.8 in weeks 12–24) and approximately 77% with Q8W. Roughly 90% APC inhibition was sustained across the interval – the pharmacodynamic basis for such infrequent dosing.
- Safety – no thrombotic events, no treatment-related adverse events, no injection-site reactions. Fibrinogen, D-dimer and FDP stayed flat, i.e. no laboratory signal of systemic hypercoagulability. Immunogenicity was low.
- Exploratory – reductions in TNF-α and a modest HJHS improvement (from 27.7 to 24.9), supporting further evaluation of potential anti-inflammatory, joint-protective effects.
By acting on locally generated APC at sites of coagulation activation, SR604 restores balance where and when it is needed, rather than suppressing anticoagulation systemically.
Congratulations to the authors – Lijun Xia, Renchi Yang, Feng Xue and co-authors.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 4, 2026, 02:44Ahmed Kotb: Emergency Management of Critical Bleeding in ITP
-
Sep 4, 2026, 02:30Mario Jimenez: KDIGO 2026 – A More Proactive Approach to IV Iron in Hemodialysis
-
Sep 4, 2026, 02:18Edgardo Alania: Edoxaban in Intracranial Haemorrhage Survivors with AF
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide